Rachna Shroff, Associate Director Clinical Research at the University of Arizona Cancer Center, posted on X by European Society For Medical Oncology, adding:
“Can we expand how we treat HCC?
ESMOGI25 data suggests we can!
Key points:
– SIERRA: CP-B7/8, PS 2, or PVT tx’ed STRIDE safely → more patients may help, but results are promising
– ABSK-011-201: FGF19+ naive AND pre-treatment, impressive ORR, but mainly Hep B patients, uncertain applicability”
Quoting ESMO‘s post:
“ESMOGI25: New combinations show promise in HCC. Favourable responses were seen with irpagratinib plus atezolizumab in FGF19+ disease.
STRIDE had acceptable safety in poor-prognosis patients in the SIERRA Clinical Trial.
Read the ESMO Daily Reporter.”
More posts featuring Rachna Shroff on OncoDaily.